Stoke Therapeutics, Inc.
STOK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001623526
In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Stoke Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 130
- +13 vs. Q3 2024
- Shares held
- 58.1M
- −152.2K (−0.3%) vs. Q3 2024
- Total value
- $640.4M
- −$75.0M (−10.5%) vs. Q3 2024
- New holders
- 29
- 40 more added
- Sold out
- 16
- 41 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STOK on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 197 | $2.49B |
| Q1 2026 | 198 | $2.31B |
| Q4 2025 | 183 | $2.13B |
| Q3 2025 | 151 | $1.57B |
| Q2 2025 | 134 | $744.0M |
| Q1 2025 | 126 | $421.6M |
| Q4 2024 | 130 | $640.4M |
| Q3 2024 | 118 | $715.5M |
| Q2 2024 | 115 | $828.5M |
| Q1 2024 | 103 | $731.7M |
| Q4 2023 | 81 | $236.9M |
| Q3 2023 | 97 | $173.1M |
| Q2 2023 | 100 | $494.8M |
| Q1 2023 | 97 | $371.8M |
| Q4 2022 | 107 | $371.8M |
| Q3 2022 | 105 | $544.4M |
| Q2 2022 | 92 | $569.4M |
| Q1 2022 | 99 | $870.6M |
| Q4 2021 | 94 | $849.6M |
| Q3 2021 | 90 | $492.4M |
| Q2 2021 | 97 | $680.3M |
| Q1 2021 | 106 | $1.49B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Stoke Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DAFNA Capital Management LLC | 171,097 | $1.89M | 0.48% | −36,330−17.5% | Reduced |
| UBS Group AG | 177,844 | $1.96M | 0.00% | +99,532+127.1% | Added |
| Susquehanna International Group, LLP | 187,908 | $2.07M | 0.00% | +53,767+40.1% | Added |
| Birchview Capital, LP | 210,000 | $2.32M | 1.88% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 254,161 | $2.80M | 0.15% | −173,002−40.5% | Reduced |
| Schonfeld Strategic Advisors LLC | 291,795 | $3.22M | 0.02% | +291,795 | New |
| Tang Capital Management LLC | 300,000 | $3.31M | 0.22% | +300,000 | New |
| Checkpoint Capital L.P. | 305,387 | $3.37M | 1.71% | +147,873+93.9% | Added |
| Norges Bank | 314,800 | $3.47M | 0.00% | +314,800 | New |
| Charles Schwab Investment Management Inc | 342,129 | $3.77M | 0.00% | +25,995+8.2% | Added |
| Deutsche Bank AG | 350,614 | $3.87M | 0.00% | −111,861−24.2% | Reduced |
| Northern Trust Corp | 350,788 | $3.87M | 0.00% | +11,635+3.4% | Added |
| Dimensional Fund Advisors LP | 538,900 | $5.94M | 0.00% | +273,890+103.4% | Added |
| Granahan Investment Management Inc | 567,689 | $6.26M | 0.26% | −77,281−12.0% | Reduced |
| MPM Oncology Impact Management LP | 685,826 | $7.56M | 1.07% | +206,374+43.0% | Added |
| Geode Capital Management, LLC | 877,095 | $9.68M | 0.00% | +6,264+0.7% | Added |
| Marshall Wace, LLP | 951,432 | $10.5M | 0.01% | −719,301−43.1% | Reduced |
| Assenagon Asset Management S.A. | 1,350,925 | $14.9M | 0.03% | +38,446+2.9% | Added |
| Goldman Sachs Group Inc | 1,368,967 | $15.1M | 0.00% | −24,793−1.8% | Reduced |
| State Street Corp | 1,587,663 | $17.5M | 0.00% | −141,225−8.2% | Reduced |
| Siren, L.L.C. | 2,000,000 | $22.1M | 0.97% | +2,000,000 | New |
| Vanguard Group Inc | 2,731,198 | $30.1M | 0.00% | −28,049−1.0% | Reduced |
| Toronto Dominion Bank | 3,173,258 | $35.0M | 0.07% | +3,173,258 | New |
| Morgan Stanley | 3,437,244 | $37.9M | 0.00% | −768,063−18.3% | Reduced |
| Redmile Group, LLC | 4,593,629 | $50.7M | 3.53% | −119,880−2.5% | Reduced |
| Baker Bros. Advisors LP | 4,633,838 | $51.1M | 0.55% | +265,395+6.1% | Added |
| RTW Investments, LP | 5,123,525 | $56.5M | 0.85% | +471,240+10.1% | Added |
| Lynx1 Capital Management LP | 5,187,191 | $57.2M | 21.45% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,887,511 | $64.9M | 0.00% | +317,361+5.7% | Added |
| Skorpios Trust | 6,906,181 | $76.2M | 99.80% | −2,000,000−22.5% | Reduced |
| Cowen and Company, LLC | 0 | $0 | 0.00% | −3,244,498−100.0% | Sold out |
| Element Capital Management LLC | 0 | $0 | 0.00% | −96,380−100.0% | Sold out |
| Eversept Partners, LP | 0 | $0 | 0.00% | −52,006−100.0% | Sold out |
| EAM Investors, LLC | 0 | $0 | 0.00% | −30,781−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −21,432−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −14,500−100.0% | Sold out |
| Arrowstreet Capital, Limited Partnership | 0 | $0 | 0.00% | −13,337−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −11,955−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −1,845−100.0% | Sold out |
| Stone House Investment Management, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −139−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −119−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −32−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Planning Capital Management Corp | – | – | – | – | Not filed |